IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

On Tuesday, IGM Biosciences Inc. IGMS announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases.

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives stepped down.

Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover

The biotechnology company says it will focus only on autoimmune diseases.

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Tuesday.

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & Autoimmunity, will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024, at 9:00 a.m. EDT.

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $1.43 per share a year ago.

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates

– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 –

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?

MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.33 per share a year ago.

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT.

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock?

Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases

IGM Biosciences Announces Refocusing of Sanofi Collaboration

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT.

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.19 per share a year ago.

IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet

The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade

IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024. The global lupus market is projected to grow to $6.78 billion by 2032 and the global Rheumatoid Arthritis drugs market size is projected to reach $38.61 billion by 2032. Two ongoing studies, one single-arm and one randomized, using Aplitabart for the treatment of patients with 2nd-line metastatic colorectal cancer, expected in the 2nd half of 2024.

News for IGM Biosciences Inc Stock (IGMS)